The study plans to examine results from 92 surgeries, the first of which was completed on Dec. 1 at National Taiwan University in Taipei. The study will follow patients for one year who are treated for focal chondral or osteochondral knee lesions. The trial will provide evidence for pre-market approval from the Taiwan Food and Drug Administration.
The technology incorporates a tissue processing system that prepares the patients’ own cartilage for delivery on the site of a cartilage defect. The single-stage procedure is designed to increase the potential for cartilage regeneration using both mechanical and chemical processing.
Related Articles on Orthopedic Devices:
Amp Orthopedics Initiates Knee & Shoulder Device Clinical Trials
K2M Names Don O’Hearn Senior Vice President of Sales in Americas
39 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in November
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
